Acutus Medical, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0051111096
USD
0.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Acutus Medical, Inc. stock-summary
stock-summary
Acutus Medical, Inc.
Pharmaceuticals & Biotechnology
Acutus Medical, Inc. is an arrhythmia management company. The Company designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. The Company’s product portfolio includes access sheaths, transseptal crossing tools, diagnostic and mapping catheters, ablation catheters, mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Its AcQMap System consists of the single-use AcQMap catheter as well as its console, workstation and software algorithms. With 48 ultrasound transducers interspersed between 48 biopotential electrodes, its mapping catheter collects the data required to create a map of the cardiac anatomy and electrical propagation pathways and patterns. The Company’s software algorithms analyze the biopotential data and maps any type of arrhythmia, including atrial fibrillation, as well as all supraventricular tachycardias and ventricular arrhythmias.
Company Coordinates stock-summary
Company Details
2210 Faraday Ave Ste 100 , CARLSBAD CA : 92008-7225
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 4 Schemes (4.81%)

Foreign Institutions

Held by 4 Foreign Institutions (0.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. R. Scott Huennekens
Executive Chairman of the Board
Mr. Vince Burgess
President, Chief Executive Officer, Director
Dr. David Bonita
Independent Director
Dr. Andrew ElBardissi
Independent Director
Mr. Jim Hinrichs
Independent Director
Dr. Shahzad Malik
Independent Director
Dr. Shaden Marzouk
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
7 Million
(Quarterly Results - Dec 2024)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million (Micro Cap)

stock-summary
P/E

0.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.68

stock-summary
Return on Equity

-0.01%

stock-summary
Price to Book

-0.00